Taysha Gene Therapies Reports Q3 2026 Results; Cash of $422.8 Million
Taysha Gene Therapies reported a Q3 2026 net loss of $39.1M, up from $32.7M a year earlier, with zero revenue. R&D and G&A expenses increased. Cash reserves were $422.8M. TSHA-102 trials for Rett syndrome are ongoing, with interim data and FDA feedback expected in 2027. Cash is expected to last into 2H 2028.


